InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
3
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-9.2%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by SOLAND DANIEL B, Chief Operating Officer. Director active across 3 companies, notably Idera Pharmaceuticals, INC.. In total, 5 reports have been logged. Split: 3 buys · 0 sell. Total volume traded: €122k. History available since 18 June 2021. The latest transaction was disclosed on 1 August 2023 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations5 total
6,652 sharesCommon StockSEC:0001415889-24-015085:0
15,000 shares@ US$1.62100.0% of flowOrdinary SharesSEC:0001209191-23-044458:0
Ideal exit: 27 Apr 2024 (T+270)
3,059 sharesCommon StockSEC:0001209191-23-034699:0
50,000 shares@ US$1.1950.0% of flowCommon StockSEC:0001415889-21-003112
Ideal exit: 15 Mar 2022 (T+270)
50,000 shares@ US$1.1950.0% of flowCommon StockSEC:0001415889-21-003112:0
Ideal exit: 15 Mar 2022 (T+270)
5 of 5 declarations
About SOLAND DANIEL B
Daniel B. Soland is the Chief Operating Officer of IDERA PHARMACEUTICALS, INC. In this role, he is responsible for managing the daily operations of the company. His expertise in the pharmaceutical sector and ability to lead teams enable him to optimize operational processes and improve efficiency.
